Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 0.72 |
| ▸ | RXRB | P28702 | 7/20 | 0.72 |
| ▸ | RXRG | P48443 | 7/20 | 0.72 |
| ▸ | RARA | P10276 | 4/20 | 0.72 |
| ▸ | RARB | P10826 | 4/20 | 0.72 |
| ▸ | RARG | P13631 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12181011 | 0.89 | RXRA (0.88) | RXRARXRBRXRGRARARARB | |
| SCHEMBL5540253 | 0.85 | RXRA (0.80) | RXRARXRBRXRGRARARARB | |
| SCHEMBL726140 | 0.84 | RXRA (1.00) | RXRARXRBRXRGRARARARB | |
| SCHEMBL292500 | 0.84 | RXRA (0.83) | RXRARXRBRXRGRARARARB | |
| SCHEMBL30054740 | 0.84 | RXRA (1.00) | RXRARXRBRXRGRARARARB | |
| SCHEMBL4915388 | 0.83 | RXRA (0.68) | RXRARXRBRXRGRARARARB | |
| SCHEMBL4009257 | 0.82 | RXRA (0.76) | RXRARXRBRXRGRARARARB | |
| SCHEMBL4910483 | 0.82 | RXRA (0.76) | RXRARXRBRXRGRARARARB | |
| SCHEMBL14068170 | 0.82 | RXRA (0.55) | RXRARXRBRXRGRARARARB | |
| SCHEMBL14068140 | 0.82 | RXRA (0.69) | RXRARXRBRXRGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160338981-A1 | THERAPEUTIC METHODS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160338981-A1 | THERAPEUTIC METHODS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-11-24 | — | — | US | disclosed |
| EP-2536276-B1 | NOVEL BEXAROTENE ANALOGS | UNIV ARIZONA (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9174917-B2 | Bexarotene analogs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174917-B2 | Bexarotene analogs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2015109318-A2 | THERAPEUTIC METHODS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20120309833-A1 | NOVEL BEXAROTENE ANALOGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2012-12-06 | — | — | US | disclosed |
| US-20120309833-A1 | NOVEL BEXAROTENE ANALOGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2012-12-06 | — | — | US | disclosed |
| WO-2011103321-A1 | NOVEL BEXAROTENE ANALOGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20080234229-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234229-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2007022437-A2 | THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND METABOLIC DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234229-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | IGF1R, INSR, BRCA1 | RXRA 494/4885RXRB 487/4885RXRG 526/4885 |
| US-20160338981-A1 | THERAPEUTIC METHODS | RXRG, RXRB, RXRA | RXRA 3/4885RXRB 2/4885RXRG 1/4885 |
| US-20120309833-A1 | NOVEL BEXAROTENE ANALOGS | TBXA2R, ENPP2, CXCL8 | RXRA 14/4885RXRB 7/4885RXRG 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.